Repligen Corporation
165.05USD
-3.4800 (-2.06%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.46▼ | $0.47 | 7 | 6 |
| Next quarter | $0.58▼ | $0.6 | 2 | 13 |
| Current year | $2.06▲ | $2 | 20 | 0 |
| Next year | $2.64▲ | $2.55 | 15 | 4 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.45 | $0.54 | +0.09 (+20.4%) |
| 2026-03-31 | $0.39 | $0.48 | +0.09 (+22.9%) |
| 2025-12-31 | $0.44 | $0.49 | +0.05 (+10.4%) |
| 2025-09-30 | $0.42 | $0.46 | +0.04 (+10.6%) |
119 ratings from 24 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Wells Fargo | Maintained | Overweight | $180 $185 | Jul 30, 2026 |
| JP Morgan | Maintained | Overweight | $165 $175 | Jul 29, 2026 |
| Benchmark | Upgraded from Hold | Buy | $185 | Jul 7, 2026 |
| Evercore ISI Group | Maintained | Outperform | $150 $160 | Jul 6, 2026 |
| HSBC | Maintained | Buy | $170 $150 | Jun 3, 2026 |
| JP Morgan | Maintained | Overweight | $180 $165 | May 6, 2026 |
| Barclays | Maintained | Overweight | $145 $160 | May 6, 2026 |
| Canaccord Genuity | Maintained | Hold | $165 $145 | Apr 20, 2026 |
| Roth Capital | Initiated | Buy | $160 | Apr 17, 2026 |
| Barclays | Maintained | Overweight | $175 $145 | Apr 14, 2026 |
| Evercore ISI Group | Maintained | Outperform | $170 $140 | Apr 6, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $180 $208 | Mar 23, 2026 |
| UBS | Maintained | Buy | $200 $195 | Feb 25, 2026 |
| Barclays | Maintained | Overweight | $200 $175 | Feb 25, 2026 |
| Wells Fargo | Maintained | Overweight | $190 $180 | Feb 25, 2026 |
| Evercore ISI Group | Maintained | Outperform | $180 $170 | Feb 25, 2026 |
| UBS | Maintained | Buy | $190 $200 | Jan 16, 2026 |
| Barclays | Maintained | Overweight | $175 $200 | Dec 15, 2025 |
| Wells Fargo | Maintained | Overweight | $175 $190 | Dec 15, 2025 |
| Canaccord Genuity | Maintained | Hold | $150 $165 | Oct 29, 2025 |
| Barclays | Maintained | Overweight | $160 $175 | Oct 29, 2025 |
| Evercore ISI Group | Maintained | Outperform | $155 $175 | Oct 7, 2025 |
| Barclays | Maintained | Overweight | $150 $160 | Oct 2, 2025 |
| HSBC | Initiated | Buy | $150 | Oct 1, 2025 |
| Evercore ISI Group | Upgraded from In-Line | Outperform | $130 $155 | Sep 22, 2025 |
43 filings from 17 insiders · 15 buy / 4 sell over 6m
Officers and directors of RGEN, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Loeillot OlivierDirector; Officer, Chief Executive Officer | Sell | 3.0k | $165.90 | $504k | Sep 4, 2026 |
| Loeillot OlivierDirector; Officer, Chief Executive Officer | Tax | 2.8k | $169.61 | $482k | Sep 3, 2026 |
| Hughes ViolettaOfficer, CHIEF ACCOUNTING OFFICER | Tax | 277 | $170.02 | $47k | Sep 1, 2026 |
| Hughes ViolettaOfficer, CHIEF ACCOUNTING OFFICER | Grant | 2.5k | — | — | Mar 5, 2026 |
| KURIYEL RALFOfficer | Grant | 125 | — | — | Mar 4, 2026 |
| BYLUND JAMESChief Operating Officer | Grant | 125 | — | — | Mar 4, 2026 |
| DOUGLASS BRIAN ROBBOfficer | Grant | 2.3k | — | — | Dec 31, 2025 |
| DAWES KAREN ADirector | Sell | 275 | $161.00 | $44k | Dec 17, 2025 |
| MUIR GLENN PDirector | Exercise | 3.4k | $26.12 | $88k | Dec 16, 2025 |
| LOEILLOT OLIVIERChief Executive Officer | Sell | 7.0k | $170.00 | $1.20M | Nov 25, 2025 |
| BYLUND JAMESChief Operating Officer | Sell | 2.2k | $151.21 | $331k | Nov 18, 2025 |
| HUNT ANTHONY JOHNDirector | Exercise | 3.0k | $33.87 | $100k | Nov 13, 2025 |
| HUNT ANTHONY JOHNDirector | Sell | 20.0k | $151.01 | $3.09M | Nov 13, 2025 |
| HUNT ANTHONY JOHNDirector | Exercise | 25.0k | $33.87 | $847k | Nov 12, 2025 |
| HUNT ANTHONY JOHNDirector | Sell | 25.0k | $154.92 | $3.92M | Nov 12, 2025 |
| HUNT ANTHONY JOHNDirector | Exercise | 20.0k | $33.87 | $677k | Sep 10, 2025 |
| HUNT ANTHONY JOHNDirector | Sell | 29.1k | $116.34 | $3.51M | Sep 10, 2025 |
| HUGHES VIOLETTAOfficer | Grant | 4.1k | — | — | Sep 2, 2025 |
| MADAUS MARTIN D PH.D.Director | Buyindirect | 1.8k | $112.13 | $202k | Aug 8, 2025 |
| MHATRE ROHINDirector | Grant | 973 | — | — | May 15, 2025 |
No analyst notes on RGEN yet.
Analyst Ratings
20 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 3 | 15 | 4 | 0 | 0 | Buy2.05 |
| 1 mo ago | 3 | 15 | 4 | 0 | 0 | Buy2.05 |
| 2 mo ago | 4 | 15 | 3 | 0 | 0 | Buy1.95 |
| 3 mo ago | 4 | 14 | 4 | 0 | 0 | Buy2.00 |